Delcath Systems, Inc. (NASDAQ:DCTH – Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $15.80 and last traded at $15.81, with a volume of 298390 shares. The stock had previously closed at $15.21.
Wall Street Analyst Weigh In
A number of analysts recently issued reports on the stock. Canaccord Genuity Group reissued a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a report on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Delcath Systems in a research report on Tuesday, January 14th. Craig Hallum upped their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Stephens restated a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Finally, StockNews.com upgraded shares of Delcath Systems from a “sell” rating to a “hold” rating in a research report on Friday, October 25th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $22.25.
View Our Latest Stock Analysis on DCTH
Delcath Systems Stock Down 0.8 %
Institutional Investors Weigh In On Delcath Systems
Hedge funds have recently modified their holdings of the business. Principal Financial Group Inc. acquired a new stake in shares of Delcath Systems in the third quarter valued at about $808,000. Renaissance Technologies LLC purchased a new stake in shares of Delcath Systems in the second quarter valued at about $694,000. Geode Capital Management LLC grew its holdings in shares of Delcath Systems by 3.0% in the third quarter. Geode Capital Management LLC now owns 251,895 shares of the company’s stock valued at $2,275,000 after purchasing an additional 7,298 shares during the period. Jane Street Group LLC purchased a new stake in shares of Delcath Systems in the third quarter valued at about $110,000. Finally, Barclays PLC purchased a new stake in shares of Delcath Systems in the third quarter valued at about $104,000. 61.12% of the stock is currently owned by institutional investors and hedge funds.
Delcath Systems Company Profile
Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
See Also
- Five stocks we like better than Delcath Systems
- What is MarketRankā¢? How to Use it
- Bloom Energy: Powering the Future With Decentralized Energy
- Dividend Payout Ratio Calculator
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- Conference Calls and Individual Investors
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.